Table 3. Summary of the results of the effect sizes of MSC treatment on functional improvement.

First author/year	MSC	Source	Conventional meta-analysis						Network meta-analysis				Conventional meta-analysis
			SMD (95% CI)	Weight (%)	Subgroup analysis				SMD (95% CI)	P value	SUCRA [0–100]		Subgroup analysis
					SMD (95% CI)	P value	Weight (%)						WMD (95% CI)
Vega/2015	BM-MSCs	Allogenic	−0.47 (−1.20 to 0.26)	16.52	−0.29 (−0.64, 0.07)	0.113	69.96		−0.29 (−0.64, 0.07)	0.113	36.4		−0.49 (−1.02, 0.04)
Gupta/2016			−0.51 (−1.28 to 0.26)	14.67
Lamo-Espinosa/2016, 2018		Autologous	0.23 (−0.53 to 0.99)	15.05									−0.12 (−0.60, 0.35)
Emadedin/2018			−0.34 (−0.95 to 0.26)	23.72
Kuah/2018	AD-MSCs	Allogenic	−0.49 (−1.59 to 0.62)	7.11	−0.82 (−1.50, −0.14)	0.018	18.91		−0.82 (−1.50, −0.14)	0.018	75.6		−0.49 (−1.59 to 0.62)
Lee/2019		Autologous	−1.02 (−1.88 to −0.16)	11.8									−1.02 (−1.88 to −0.16)
Matas/2019	UC-MSCs	Allogenic	−1.02 (−1.90 to −0.13)	11.14	−1.02 (−1.90 to −0.13)	0.024	11.14		−1.02 (−1.90 to −0.13)	0.024	85.3		−1.02 (−1.90 to −0.13)